Abstract
Estrogens and insulin/Insulin like growth factor 1 (IGF-I) have potent positive effects on the proliferation of mammary epithelial cells and estrogen-dependent breast cancer cells. A cooperative crosstalk between estrogens and insulin/ IGF-I signaling pathways exists and it plays a critical role in breast carcinogenesis, tumor cell proliferation, differentiation and survival through the modulation of multiple biological events. The biological effects of estrogens are mainly mediated by the activation of estrogen receptor (ERα) whose activity is deeply influenced by the insulin/IGF-I signaling pathway. On the other hand, estrogens enhance insulin signaling by increasing the expression and/or the functional activity of some proteins involved in the insulin/IGF-I pathway. This review will focus on the critical node of the IGF-I network involved in the crosstalk with ERα and implicated in breast cancer development and progression.
Keywords: Estrogen receptor, IGF-I, IGF-IR, Shc, IRS-1, PI3K, Akt, MNAR, ErbB, EGFR
Current Cancer Drug Targets
Title: Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer
Volume: 8 Issue: 7
Author(s): Marilena Lanzino, Catia Morelli, Cecilia Garofalo, Maria Luisa Panno, Loredana Mauro, Sebastiano Ando and Diego Sisci
Affiliation:
Keywords: Estrogen receptor, IGF-I, IGF-IR, Shc, IRS-1, PI3K, Akt, MNAR, ErbB, EGFR
Abstract: Estrogens and insulin/Insulin like growth factor 1 (IGF-I) have potent positive effects on the proliferation of mammary epithelial cells and estrogen-dependent breast cancer cells. A cooperative crosstalk between estrogens and insulin/ IGF-I signaling pathways exists and it plays a critical role in breast carcinogenesis, tumor cell proliferation, differentiation and survival through the modulation of multiple biological events. The biological effects of estrogens are mainly mediated by the activation of estrogen receptor (ERα) whose activity is deeply influenced by the insulin/IGF-I signaling pathway. On the other hand, estrogens enhance insulin signaling by increasing the expression and/or the functional activity of some proteins involved in the insulin/IGF-I pathway. This review will focus on the critical node of the IGF-I network involved in the crosstalk with ERα and implicated in breast cancer development and progression.
Export Options
About this article
Cite this article as:
Lanzino Marilena, Morelli Catia, Garofalo Cecilia, Panno Luisa Maria, Mauro Loredana, Ando Sebastiano and Sisci Diego, Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer, Current Cancer Drug Targets 2008; 8 (7) . https://dx.doi.org/10.2174/156800908786241104
DOI https://dx.doi.org/10.2174/156800908786241104 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: The Human Microbiome - A Therapeutic Target for Prevention and Treatment of Chronic Disease (Executive Editor: Kieran Tuohy)]
Current Pharmaceutical Design The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Virtual Screening and Discovery of Novel Aurora Kinase Inhibitors
Current Topics in Medicinal Chemistry Interleukin-21 (IL-21) Controls Inflammatory Pathways in the Gut
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]
Current Pharmaceutical Design Drug Conjugated Nanomedicine as Prodrug Carrier
Nanoscience & Nanotechnology-Asia Taste Sensing in the Colon
Current Pharmaceutical Design SNP Technologies for Drug Discovery: A Current Review
Current Drug Discovery Technologies Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Heterogeneity in the Pathology and Molecular Biology of Breast Cancer
Current Genomics Antipsychotics as Psychosis Drugs and Neuroprotective Promoters Evaluated by Chemical QSAR - in silico and in vivo Studies
Letters in Drug Design & Discovery Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design High Throughput and Global Approaches to Gene Expression
Combinatorial Chemistry & High Throughput Screening MR Spectroscopy in Metabolic Profiling Studies of Stem Cells
Current Medical Imaging Unveiling the Transient Protein-Protein Interactions that Regulate the Activity of Human Lemur Tyrosine Kinase-3 (LMTK3) Domain by Cyclin Dependent Kinase 5 (CDK5) in Breast Cancer: An in silico Study
Current Proteomics Using Two Layers of BI-RADS Features for Locating Similar Calcification Lesions
Current Medical Imaging